| Literature DB >> 35108770 |
Hyeon-Jin Min1, Jung-Soo Park2, Jaeseok Yang3, Jihyun Yang1, Se Won Oh1, Sang-Kyung Jo1, Won Yong Cho1, Jun Gyo Gwon4, Cheol Woong Jung4, Yang-Jo Seol5, Shin-Young Park6, Myung-Gyu Kim1.
Abstract
BACKGROUND: Recent several reports have demonstrated that periodontitis is prevalent and adversely affects the survival in patients with chronic kidney disease (CKD) or end-stage kidney disease. However, its impact on transplant outcomes remains uncertain.Entities:
Keywords: Cardiovascular diseases; Graft rejection; Kidney transplantation; Periodontitis
Year: 2022 PMID: 35108770 PMCID: PMC8816407 DOI: 10.23876/j.krcp.21.097
Source DB: PubMed Journal: Kidney Res Clin Pract ISSN: 2211-9132
Baseline characteristics of recipients with periodontitis before kidney transplantation
| Characteristic | Total | Stage I and II | Stage III | Stage IV | p-value |
|---|---|---|---|---|---|
| Patient | 303 (100) | 160 (52.8) | 89 (29.4) | 54 (17.8) | |
| Age (yr) | 43.97 ± 12.28 | 39.04 ± 12.13 | 48.17 ± 10.46 | 51.69 ± 8.50 | <0.001 |
| Male sex | 205 (67.7) | 103 (64.4) | 64 (71.9) | 38 (70.4) | 0.28 |
| Body mass index (kg/m2) | 23.28 ± 3.75 | 22.44 ± 3.70 | 23.74 ± 3.24 | 25.01 ± 4.02 | <0.001 |
| Current smoker | 36 (11.9) | 14 (8.8) | 9 (10.1) | 13 (24.1) | 0.008 |
| Causes of ESKD | |||||
| Diabetes mellitus | 60 (19.8) | 18 (11.3) | 19 (21.3) | 23 (42.6) | <0.001 |
| Hypertension | 75 (24.8) | 30 (18.8) | 31 (34.8) | 14 (25.9) | 0.08 |
| Glomerulonephritis | 85 (28.1) | 62 (38.8) | 16 (18.0) | 7 (13.0) | <0.001 |
| Polycystic kidney disease | 15 (5.0) | 10 (6.3) | 5 (5.6) | 0 (0) | 0.10 |
| Others | 16 (5.3) | 15 (9.4) | 0 (0) | 1 (1.9) | 0.005 |
| Unknown | 52 (17.2) | 25 (15.6) | 18 (20.2) | 9 (16.7) | 0.66 |
| Renal replacement therapy | |||||
| Hemodialysis | 201 (66.3) | 98 (61.3) | 60 (67.4) | 43 (79.6) | 0.02 |
| Peritoneal dialysis | 49 (16.2) | 27 (16.9) | 17 (19.1) | 5 (9.3) | 0.32 |
| Preemptive | 53 (17.5) | 35 (21.9) | 12 (13.5) | 6 (11.1) | 0.04 |
| Dialysis vintage (mo) | 14.94 ± 25.80 | 14.19 ± 22.87 | 17.09 ± 30.33 | 13.53 ± 26.02 | 0.67 |
| Comorbidity | |||||
| Hypertension | 272 (89.8) | 143 (89.4) | 83 (93.3) | 46 (85.2) | 0.20 |
| Diabetes mellitus | 73 (24.1) | 22 (13.8) | 25 (28.1) | 26 (48.1) | <0.001 |
| Dyslipidemia | 185 (61.1) | 93 (58.1) | 54 (60.7) | 38 (70.4) | 0.14 |
| Ejection fraction of heart | 57.26 ± 7.19 | 58.32 ± 6.77 | 56.35 ± 6.76 | 55.54 ± 8.67 | 0.02 |
| Laboratory test | |||||
| Hemoglobin (g/dL) | 10.43 ± 1.68 | 10.44 ± 1.63 | 10.50 ± 1.88 | 10.29 ± 1.51 | 0.76 |
| Albumin (g/dL) | 3.95 ± 0.49 | 4.00 ± 0.48 | 3.90 ± 0.51 | 3.90 ± 0.48 | 0.23 |
| CRP (mg/L), 10 × hsCRP[ | 4.88 ± 15.41 | 2.80 ± 5.79 | 5.74 ± 15.07 | 9.68 ± 28.93 | 0.01 |
| LDL (mg/dL) | 85.13 ± 30.47 | 84.70 ± 32.57 | 83.13 ± 28.67 | 89.62 ± 26.88 | 0.46 |
| Triglyceride (mg/dL) | 125.95 ± 85.88 | 124.59 ± 78.57 | 125.51 ± 90.30 | 130.62 ± 99.28 | 0.91 |
| Calcium (mg/dL) ×phosphate (mg/dL) | 47.96 ± 16.42 | 47.24 ± 16.45 | 49.57 ± 16.44 | 47.42 ± 16.42 | 0.55 |
| iPTH (pg/mL) | 250.66 ± 246.75 | 256.21 ± 284.45 | 243.97 ± 208.09 | 245.48 ± 182.61 | 0.92 |
| Donor age (yr) | 45.86 ± 10.92 | 46.21 ± 10.50 | 45.99 ± 11.37 | 44.63 ± 11.52 | 0.65 |
Data are expressed as number (%) or mean ± standard deviation.
CRP, C-reactive protein; ESKD, end-stage kidney disease; hsCRP, high sensitivity CRP; iPTH, intact parathyroid hormone; LDL, low-density lipoprotein.
hsCRP of Seoul National University Hospital converted to CRP of Korea University Medical Center with s conversion factor (10) by method of Milone et al. [9].
Immunologic characteristic of recipients with periodontitis
| Variable | Total | Stage I and II | Stage III | Stage IV | p-value |
|---|---|---|---|---|---|
| No. of HLA mismatch | 3.39 ± 1.57 | 3.19 ± 1.61 | 3.61 ± 1.60 | 3.63 ± 1.32 | 0.06 |
| Induction immunosuppressive agent | |||||
| Simulect[ | 263 (86.8) | 143 (89.4) | 76 (85.4) | 44 (81.5) | 0.12 |
| Maintenance immunosuppressive agent (initial) | |||||
| Tacrolimus-based regimen[ | 285 (94.1) | 150 (93.8) | 82 (92.1) | 53 (98.1) | 0.26 |
| Maintenance immunosuppressive agent (at 1 yr) | |||||
| Tacrolimus-based regimen | 249 (91.5) | 131 (92.3) | 71 (88.7) | 47 (94.0) | 0.95 |
| Tacrolimus + mycophenolate | 207 (76.1) | 105 (73.9) | 60 (75.0) | 42 (84.0) | 0.20 |
| Tacrolimus + sirolimus | 27 (9.9) | 16 (11.3) | 9 (11.3) | 2 (4.0) | 0.20 |
| Tacrolimus + bredinin | 15 (5.5) | 10 (7.0) | 2 (2.5) | 3 (6.0) | 0.51 |
| Cyclosporine + mycophenolate | 23 (8.5) | 11 (7.7) | 9 (11.3) | 3 (6.0) | 0.95 |
Data are expressed as mean ± standard deviation or number (%).
HLA, human leukocyte antigen.
Simulect or anti-thymocyte globulin were used as induction immunosuppressive agent.
Initial maintenance immunosuppressive agent was tacrolimus- or cyclosporine-based regimen.
Clinical outcome of patients with periodontitis after KT
| Variable | Total (n = 303) | Stage I and II (n = 160) | Stage III (n = 89) | Stage IV (n = 54) | p-value |
|---|---|---|---|---|---|
| GFR (mL/min/1.73 m2) | |||||
| 1-Month GFR | 69.82 ± 19.91 | 69.71 ± 20.50 | 70.12 ± 17.73 | 69.62 ± 21.83 | 0.99 |
| 1-Year GFR[ | 65.67 ± 16.96 | 64.68 ± 18.50 | 67.19 ± 12.61 | 66.43 ± 18.03 | 0.56 |
| 3-Year GFR[ | 67.31 ± 17.71 | 67.07 ± 19.76 | 67.96 ± 13.41 | 67.14 ± 14.55 | 0.95 |
| Rejection | |||||
| AMR | 18 (5.9) | 9 (5.6) | 4 (4.5) | 5 (9.3) | 0.47 |
| ATMR or borderline ATMR | 113 (37.3) | 69 (43.1) | 31 (34.8) | 13 (24.1) | 0.01 |
| Graft loss | 14 (4.6) | 7 (4.4) | 4 (4.5) | 3 (5.6) | 0.75 |
| Infection | |||||
| Bacterial infection | 71 (23.4) | 39 (24.4) | 19 (21.3) | 13 (24.1) | 0.84 |
| CMV viremia | 43 (14.2) | 20 (12.5) | 17 (19.1) | 6 (11.1) | 0.82 |
| BK viremia | 53 (17.5) | 33 (20.6) | 15 (16.9) | 5 (9.3) | 0.06 |
Data are expressed as mean ± standard deviation or number (%).
AMR, acute antibody-mediated rejection; ATMR, acute T cell-mediated rejection; CMV, cytomegalovirus; GFR, glomerular filtration rate; KT, kidney transplantation.
A total of 262 patients who followed up for more than 1 year after KT were included.
A total of 202 patients who followed up for more than 3 years after KT were included.
Risk factors to predict acute T cell-mediated rejection
| Variable | Crude model | Age, sex-adjusted model | Multivariate model | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Sex (female) | 0.69 (0.42–1.16) | 0.16 | ||||
| Age (yr) | 0.98 (0.96–0.99) | 0.04 | ||||
| Year of KT | 1.11 (0.99–1.25) | 0.06 | 1.13 (1.01–1.27) | 0.03 | ||
| Donor age (yr) | 1.03 (1.00–1.05) | 0.03 | 1.02 (1.00–1.05) | 0.04 | ||
| HLA mismatch | 1.15 (0.99–1.34) | 0.07 | 1.23 (1.05–1.45) | 0.01 | 1.39 (1.10–1.77) | 0.006 |
| Relationship | ||||||
| Unrelated | 1.62 (0.98–2.68) | 0.06 | 2.02 (1.17–3.47) | 0.01 | ||
| Induction IS | ||||||
| ATG | 0.38 (0.17–0.85) | 0.38 | 0.38 (0.17–0.86) | 0.02 | ||
| Maintenance IS at 1 yr | ||||||
| Tacrolimus-based | 1.00 | 1.00 | ||||
| CsA-based | 2.60 (0.90–7.54) | 0.08 | 2.47 (0.84–7.24) | 0.10 | ||
| CMV viremia | 1.56 (0.82–3.00) | 0.18 | 1.55 (0.80–3.00) | 0.19 | ||
| CRP (mg/L), 10 × hsCRP | 0.97 (0.94–1.01) | 0.09 | 0.9 (0.93–1.00) | 0.06 | ||
| HbA1c (% of THb) | 0.84 (0.61–1.16) | 0.29 | 0.90 (0.66–1.24) | 0.53 | ||
| Periodontitis | ||||||
| Stage I and II | 1.0 | 1.00 | 1.00 | |||
| Stage III | 0.71 (0.41–1.21) | 0.20 | 0.77 (0.43–1.36) | 0.36 | 1.42 (0.59–3.41) | 0.44 |
| Stage IV | 0.42 (0.21–0.84) | 0.01 | 0.48 (0.23–1.01) | 0.05 | 0.28 (0.08–098) | 0.05 |
ATG, anti-thymocyte globulin; CI, confidence interval; CMV, cytomegalovirus; CRP, C-reactive protein; CsA, cyclosporine; HbA1c, hemoglobin A1c; IS, immunosuppressant; KT, kidney transplantation; OR, odds ratio.
In the age, sex-adjusted model, an enter selection approach was adopted. In the multivariate logistic analysis model, age, male sex, donor age, CRP, number of human leukocyte antigen mismatch, relationship, year of KT, induction immunosuppressive agent, maintenance immunosuppressive agent at 1 year, stage of periodontitis were adjusted. Multivariate logistic regression was performed with variables with p-value less than 0.3 in univariate analysis; a backward stepwise selection approach was adopted. All laboratory data were examined prior to KT.
Cardiovascular diseases in patients with a follow-up period of 3 years or more
| Variable | Total (n = 202) | Stage I and II (n = 127) | Stage III (n = 52) | Stage IV (n = 23) | p-value |
|---|---|---|---|---|---|
| Cardiovascular disease | 9 (4.5) | 3 (2.4) | 2 (3.8) | 4 (17.4) | 0.006 |
| Coronary artery disease[ | 8 (4.0) | 3 (2.4) | 2 (3.8) | 3 (13.0) | 0.03 |
| Cerebrovascular disease | 1 (0.5) | 0 (0) | 0 (0) | 1 (4.3) | 0.03 |
Data are expressed as number (%).
Coronary artery disease: unstable angina, myocardial infarction.
Risk factors to predict new-onset coronary artery disease
| Variable | Crude model | Multivariate model | ||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Female sex | 0.31 (0.04–2.59) | 0.28 | ||
| Age (yr) | 1.02 (1.00–1.17) | 0.04 | ||
| Year of KT | 1.13 (0.74–1.71) | 0.58 | ||
| HbA1c (% of THb) | 1.35 90.83–2.18) | 0.23 | ||
| Donor age (yr) | 0.95 (0.89–1.01) | 0.09 | ||
| Ca (mg/dL) | 1.54 (0.66–3.59) | 0.32 | ||
| iPTH (pg/mL) | 0.997 (0.99–1.00) | 0.24 | ||
| Body mass index | 1.09 (0.90–1.32) | 0.37 | ||
| Dyslipidemia | 1.49 (0.36–6.12) | 0.58 | ||
| Causes of ESKD | ||||
| Diabetes mellitus | 7.07 (1.62–30.93) | 0.009 | 4.73 (1.08–20.77) | 0.04 |
| Glomerulonephritis | 0.26 (0.03–2.15) | 0.21 | ||
| Periodontitis stage | ||||
| Stage I and II | 1.00 | |||
| Stage III | 1.65 (0.27–10.20) | 0.59 | ||
| Stage IV | 6.20 (1.17–32.89) | 0.03 | ||
CI, confidence interval; ESKD, end-stage kidney disease; iPTH, intact parathyroid hormone; KT, kidney transplantation; OR, odds ratio.
In the multivariate logistic analysis model, age, male sex, donor age, hemoglobin A1c, iPTH, cause of end-stage renal disease (diabetes mellitus, glomerulonephritis), year of KT, stage of periodontitis were adjusted. Multivariate logistic regression was performed with variables with p-value less than 0.3 in univariate analysis; a backward stepwise selection approach was adopted. All laboratory data were examined prior to KT. Dyslipidemia was defined as those with low-density lipoprotein cholesterol greater than 100 mg/dL or triglyceride greater than 500 mg/dL or under lipid-lowering agent.